Operating under a business-to-business model, the company has demonstrated excellence in developing, manufacturing and marketing complex injectables with presence across the value chain enabling exponential growth. Gland Pharma is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Cyborg Score Rationale
The company faced revenue decline of 0.85% in 2024 and earnings decreased 9.57%, though recent quarters show margin stability. GLAND underperformed both the Indian pharmaceuticals industry and broader market over the past year. However, strong global diversification and capacity expansion initiatives provide growth potential.
Top Insights
Q2 FY2025-26 revenue declined 0.1% YoY to ₹1486.88 crore with net profit down 9.6% to ₹183.68 crore, though full-year FY2025-26 revenue reached ₹5830.11 crore with profit of ₹698.53 crore.
Company pursuing aggressive capacity expansion, complex product launches with diversification into emerging markets and advanced manufacturing formats to enhance earnings stability.
Market cap of ₹30,455 crore (up 15.7% in 1 year) with return on equity of just 9.22% over last 3 years indicates efficiency challenges.
Pashamylaram facility received Good Manufacturing Practices compliance certificate from Danish Medicines Agency, strengthening regulatory credentials.
Named Competitors
Injectable Formulations — Global injectable and pharmaceutical major
Injectable Formulations — Indian pharmaceutical manufacturer
Injectable Formulations — API and formulation manufacturer
Recent Developments
(Feb 2026) Analyst/investor meeting with Investec scheduled for February 12, 2026
(Sept 2025) Q2 FY2025-26 results released showing YoY revenue decline with margin pressures
(Dec 2024) Q3 FY25 results reported with 6.7% YoY net profit growth despite analyst downgrades
Open the full interactive Gland Pharma Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.